<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: STENOCARE</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Mon, 12 Jun 2023 09:25:59 GMT</pubDate>
  <item>
    <title>STENOCARE Units Rights Issue subscribed to 127%</title>
    <pubDate>Mon, 12 Jun 2023 09:25:59 GMT</pubDate>
    <link>https://www.pressen.se/850953583.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on June 12, 2023. The subscription period in the Initial Rights Issue of the Units Rights Issue of STENOCARE A/S (“Stenocare” or the “Company”) ended on 8 June 2023.</description>
    <source>DI</source>
  </item>


  <item>
    <title>High profiled medical doctor and entrepreneur joins STENOCARE’s ongoing share-issue</title>
    <pubDate>Tue, 06 Jun 2023 06:00:00 GMT</pubDate>
    <link>https://www.pressen.se/846304877.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO Inspired about the potential of medical cannabis when prescribed by doctors to patients in pain, Hans Wittrup, M.D., Ph.</description>
    <source>DI</source>
  </item>
  <item>
    <title>STENOCARE reports on significant progress in development of its new innovative medical cannabis product</title>
    <pubDate>Fri, 02 Jun 2023 10:56:42 GMT</pubDate>
    <link>https://www.pressen.se/843501353.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) has selected an international, highly experienced partner to produce a new and innovative medical cannabis oil product, that has the potential to revolutionize the industry and offer patients improved treatment effect. The new product is based on a patented oil technology, that Stenocare has global exclusivity to use for medical cannabis..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Potentialen är enorm för medicinsk cannabis när Europa legaliserar ⎮ #Investtalks</title>
    <pubDate>Thu, 01 Jun 2023 18:31:04 GMT</pubDate>
    <link>https://www.pressen.se/842982414.html</link>
    <description>Marknaden för medicinsk cannabis har stor tillväxtpotential när land för land överväger legaliseringen ute i Europa. Utmaningen är att bemöta de missuppfattningar om läkemedlet som fortfarande finns. – Det är bara en fråga om kunskap, tålamod och tid, menar Thomas Skovlund Schnegelsberg, vd för danska bolaget Stenocare A/S – som just har tillkännagett en företrädesemission med Units för att anskaffa kapital för deras tillväxtacceleration..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Stenocare product approved and ready for sale in germany</title>
    <pubDate>Thu, 25 May 2023 06:00:00 GMT</pubDate>
    <link>https://www.pressen.se/837338531.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on May 25, 2023. The new Stenocare medical cannabis oil product has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) for prescription-based sales to German patients.</description>
    <source>DI</source>
  </item>
  <item>
    <title>STENOCARE företrädesemission med Units – startar i dag</title>
    <pubDate>Wed, 24 May 2023 06:02:00 GMT</pubDate>
    <link>https://www.pressen.se/836559072.html</link>
    <description>­STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (&quot;Stenocare&quot;) meddelade den 15 maj 2023 att bolaget kommer att ta in upp till 30 miljoner DDK i en företrädesemission med Units på Nasdaq First North Growth Market. Idag, den 24 maj, är första dagen för investerare och aktieägare att teckna de nya aktierna och teckningsoptionerna..</description>
    <source>DI</source>
  </item>
  <item>
    <title>STENOCARE A/S: Unit Rights Issue of up to 29.7 mDKK</title>
    <pubDate>Mon, 15 May 2023 11:45:15 GMT</pubDate>
    <link>https://www.pressen.se/830084062.html</link>
    <description>15 May 2023 | Stenocare A/S | Company announcement | Inside Information NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Stenocare A/S (“Stenocare” or “the Company”) announces a rights issue of units (the “Issue”) consisting of shares, warrants of series TO1 and warrants of series TO2 (“Units”). The Issue amounts to three transactions, including an imminent share-issue (the “Initial Rights Issue”) and two subsequent warrant exercises of TO1 and TO2 (the “Warrants”), with total gross proceeds of up to 29.</description>
    <source>DI</source>
  </item>
  <item>
    <title>STENOCARE A/S (“Stenocare”) delivered products to its 5 markets during Q4 2022 corresponding to net sales of 2.8 mDKK and is on track for its sales expectations for 2023 in the range of 15-20 mDKK</title>
    <pubDate>Mon, 09 Jan 2023 07:00:00 GMT</pubDate>
    <link>https://www.pressen.se/733326292.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Investor Update: The first shipment of Stenocare medical cannabis oil products has arrived in Norway and the products are ready for patients.</title>
    <pubDate>Tue, 03 Jan 2023 07:04:00 GMT</pubDate>
    <link>https://www.pressen.se/727936843.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO STENOCARE A/S (“Stenocare”) announced on October 28, 2022, that it would enter Norway with prescription-based medical cannabis oil products. At the end of December 2022, the first shipment was successfully completed to Apotek 1, a leading chain of pharmacies and the products are now ready for nationwide sales and delivery to patients through prescription..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Investor Update: Today, the new STENOCARE CBD medical cannabis oil product is available in Denmark. The first shipment has arrived, and sales of the product can begin.</title>
    <pubDate>Mon, 02 Jan 2023 14:27:53 GMT</pubDate>
    <link>https://www.pressen.se/727180885.html</link>
    <description>STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER:  STENO   STENOCARE A/S (“Stenocare”) announced October 14, 2022, that it had received approval to supply a new CBD 20 mg/mL medical cannabis oil product to the Danish Pilot Programme. With this new product, Stenocare is the only supplier of CBD oil products under the Pilot Programme and the new products are officially ready for sales across the entire country as of today..</description>
    <source>DI</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.16059303283691 s -->